Diverse Studies

  1. An open-label, single-dose study of the effects of 100 mg of XXX on the pharmacokinetic profile, safety and tolerability in patients with compromised hepatic function.
  2. The pharmacokinetics of a single oral dose of XXX in healthy adults and in patients with impaired hepatic function.
  3. XXX in hypertensives with ventricular ectopy.
  4. A placebo controlled study of ascending single oral doses of XXX in patients with frequent ventricular ectopy, to examine safety, pharmacodynamics and pharmacokinetics.
  5. Effects of XXX on oxygen uptake in patients with congestive heart failure.
  6. A multicenter, double-blind, placebo controlled study of the effects of 100 mg or 75 mg XXX on duration of exercise by treadmill testing and disease symptoms for up to 12 weeks in congestive heart failure patients who are symptomatic on digitalis and diuretics.
  7. A double-blind, parallel-group formulation cross-over placebo controlled, multicenter study comparing the activity of a new formulation of XXX administered BID to suppress VPDs.
  8. A prospective randomized double-blind, placebo-controlled, multicenter, parallel-groups comparison of the efficacy and safety of XXX low dose (3.0-9.0 mg), high dose (7.5-22.5 mg) and XXX (15-45 mg) in outpatients with generalized anxiety disorder.
  9. A prospective, randomized, double-blind, multicenter, parallel-groups comparison of the efficacy and safety of XXX low dose (3.0-7.0 mg) high dose (7.5-17.5 mg) and placebo in elderly outpatients with anxiety symptoms.
  10. A flexible-dose, placebo-controlled study of XXX tablets and XXX tablets in the treatment of generalized anxiety disorder.
  11. Double-blind parallel comparison of XXX and XXX in outpatients with major depression.
  12. No-effect and lowest effective dose-finding study of XXX (Prostaglandin E1, PGE1) sterile powder (S.Po.) in patients with erectile dysfunction.
  13. Pilot study with XXX sterile powder (S.Po.) (ProstaglandinE1, PGE1) in patients with erectile dysfunction.
  14. The effects of XXX on the pharmacokinetics of Digoxin.
  15. XXX vs placebo - preventing GU relapse in long term NSAID.
  16. A phase III randomized, placebo-controlled, double-blind, dose response comparison of XXX (XX, sodium) 4.5 G and 6.75 G daily vs placebo in patients with active mild or moderate ulcerative colitis.
  17. An open label continuation of Prot. 101 evaluating XXX (XX sodium) 6.75 G/day for acute treatment and 3.0 G/day for maintenance therapy of patients with mild or moderate ulcerative colitis.
  18. Assessment of bone mineral density in women receiving XXX contraceptive injection.Addendum: Evaluation of single dose and multiple dose pharmacokinetics of XXX contraceptive injection.
  19. A multicenter, double-blind, parallel group safety and efficacy comparison of placebo and XXX (XXX-180291) in subjects with intermittent claudication.
  20. Assessment of bone mineral density in women receiving XXX contraceptive injection.Addendum: Evaluation of single dose and multiple dose pharmacokinetics of XXX contraceptive injection.
  21. A Double-Blind, Parallel Group Comparative Trial of XXX (200 µg and 300 µg daily) Versus Fluvastatin (20 mg and 40 mg daily) in Subjects with Hypercholesterolemia.
  22. A Two-Period, Open-Label, Randomizedm, Cross-Over Study in Healthy Postmenopausal Female Subjects to Demonstrate the Bioequivalence of Two XXX Low-Dose Formulations.
  23. A Study of the Effects of XXX on Digoxin Pharmacokinetics in Digoxin Medicated Patients.
  24. A Randomized, Double-Blind, Placebo-Controlled, Ascending, Multiple-Dose, Safety and Tolerance Study of XXX Administered to Patients with Liver Cirrhosis and Ascites.
  25. A Parallel Dose-Response Study of Sustained-Released XXX in Patients with Congestive Heart Failure.
  26. A Randomized, Double-Blind Multicenter Comparison of the Safety and Effect of Three Dose Levels of XXX and Placebo in the Treatment of Patients with Hyponatremia.
  27. A Randomized, Double-blind, Placebo-Controlled Dose Ranging Study of a 14-Day Course of XXX in Patients with Vascular Disease.
  28. A Randomized, Single-Dose, Parallel Group Study to Evaluate the Rate and Extent of Absorption of XXX (XXX) 75, 150 and 300 mcg Tablets Using and Athyreotic Patient.
  29. A Study of the Pharmacokinetics of Oral XXX in Patients with Moderate or Severe Hepatic Impairment.
  30. A Multi-Center, Open-Label, Multiple Dose, Replicate Design Study, of the XXX Variability of a Prototype XXX Tablet in Hypothyroid, Adult, Female, Patients.
  31. Transfusion of XXX Fresh Frozen Plasma in Patients with Congenital Coagulation Factor Deficiencies.
  32. A Six-Week, Double-Blind, Placebo Controlled Multicenter Study to Evaluate the Safety and Efficacy of XXX in the Treatment of Hemophilic Arthropaty.
  33. A Bioequivalence Study of XXX Tablets Intended for Commercial Use and XXX Tablets Used in Clinical Studies Administered Orally to Individuals with Current or Previous Chronic Hepatitis C (CHC) Infection.
  34. Pharmacokinetics of XXX in Subjects with Chronic Liver Disease.
  35. A Multi-Center, Placebo Controlled Evaluation of the Safety and Efficacy of Two Dosage Levels of XXX (75mg and 125mg) Administered Once Daily by Subcutaneous Injection for the Treatment of Active Ulcerative Colitis.
  36. Clinical Protocol for a Double-Blind, Randomized, Parallel-Group Comparison Study of the Safety of XXX vs. Rofecoxib inTreated Patients with Osteoarthritis (XXX).